Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Shares of liquid biopsy company ANGLE plc (LON: AGL) are climbing on Tuesday after cancer research institute, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, published results of new work undertaken in triple-negative breast cancer (TNBC) patients using ANGLE's Parsotix system.
Researchers used the Parsotix system to isolate circulating tumour cells (CTCs) in patients with recurrent disease and analysed these concurrently with circulating tumour DNA in the blood.
Using the system for CTC enrichment along with the DEPArray system for automated single-CTC retrieval, the study showed that in the vast majority of recurrent cancer cases, CTCs identified were non-epithelial and would not have been detected by any of the commercially available epithelial antibody-based approaches, including the market leader.
ANGLE said multiple druggable targets were identified using the system.
It included PI3K, HER2, BRAF, platinum-resistance signalling, and regulation of immune response correlating to at least 12 FDA approved drug treatment options. ANGLE said, “this is of particular significance in patients with TNBC where endocrine therapy or anti-HER2 agents are ineffective and therefore treatment options are limited.”
TNBC accounts for around 10-15% of all breast cancer cases in the US, according to ANGLE.
ANGLE Founder and CEO Andrew Newland commented: “The use of the Parsortix system in uncovering potential new therapeutic targets through its ability to harvest mesenchymal as well as epithelial CTCs for analysis showcases further evidence of the advantages of using the Parsortix system over antibody-based CTC systems.
“ANGLE's ability to provide this actionable information could help patients who have limited treatment options and should prove highly attractive to drug developers looking for new approaches for hard-to-treat cancers, such as TNBC.”
ANGLE's share price is currently trading at 114.5p, up 3.15% from Monday's close.
ANGLE shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are ANGLE shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .